Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28130368 | 0.82 | OPRD1 (0.73) | MRGPRX2OPRD1OPRM1OPRK1ADRB1 | |
| SCHEMBL20983505 | 0.82 | MRGPRX2 (0.82) | MRGPRX2OPRD1OPRM1OPRK1ADRB1 | |
| SCHEMBL8362208 | 0.81 | MRGPRX2 (0.81) | MRGPRX2OPRD1OPRM1OPRK1 | |
| SCHEMBL29459625 | 0.81 | MRGPRX2 (1.00) | MRGPRX2OPRD1OPRM1OPRK1ADRB1 | |
| SCHEMBL5108263 | 0.81 | MRGPRX2 (1.00) | MRGPRX2OPRD1OPRM1OPRK1ADRB1 | |
| SCHEMBL19463540 | 0.80 | OPRD1 (0.72) | MRGPRX2OPRD1OPRM1OPRK1ADRB1 | |
| Hydrochloric Acid SCHEMBL8168636 | 0.80 | MRGPRX2 (0.98) | MRGPRX2OPRD1OPRM1OPRK1ADRB1 | |
| SCHEMBL547920 | 0.77 | OPRD1 (0.70) | MRGPRX2OPRD1OPRM1OPRK1ADRB1 | |
| SCHEMBL27483471 | 0.77 | MRGPRX2 (0.76) | MRGPRX2OPRD1OPRM1OPRK1ADRB1 | |
| SCHEMBL3476236 | 0.76 | OPRD1 (0.68) | MRGPRX2OPRD1OPRM1OPRK1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| WO-2025128946-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4536138-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536139-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4507825-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | Board of Regents, The University of Texas System (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024211329-A2 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024044315-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023244821-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL SYSTEM (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244797-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL SYSTEM (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023200850-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | MRGPRX2 1275/4885OPRD1 4518/4885OPRM1 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.